Ipilimumab: all 592 studies that test it

Page 2 of 6. Open to participants first (76), then studies with results posted, then the rest; newest registration first within each.

• A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaActive, not recruitingNCT03999749Phase 2Results posted
• IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for MelanomaTerminatedNCT03958383Phase 1/2Results posted
• Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced MelanomaActive, not recruitingNCT03929029Phase 1Results posted
• Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results posted
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingNCT03912064Phase 1Results posted
• Optune Device - TT Field Plus Nivolumab and Ipilimumab for Melanoma With Brain MetastasisTerminatedNCT03903640Phase 2Results posted
• Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainCompletedNCT03873818Phase 2Results posted
• Radiation and Combination Immunotherapy for MelanomaCompletedNCT03850691Phase 2Results posted
• Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic CancersActive, not recruitingNCT03816332Phase 1Results posted
• Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell CarcinomaTerminatedNCT03799445Phase 2Results posted
• NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast CancerActive, not recruitingNCT03789110Phase 2Results posted
• Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland CancersCompletedNCT03749460Phase 1/2Results posted
• Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)CompletedNCT03739710Phase 2Results posted
• Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II ExpressionTerminatedNCT03724968Phase 2Results posted
• Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal TumorsTerminatedNCT03693846Phase 2Results posted
• Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular CarcinomaCompletedNCT03682276Phase 1/2Results posted
• A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)CompletedNCT03668119Phase 2Results posted
• Radiation and Chemotherapy With Ipilimumab Followed by Nivolumab for Patients With Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03663166Phase 1/2Results posted
• A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung CancerCompletedNCT03575793Phase 1/2Results posted
• Phase II Clinical Trial of NIVO-IPI-TAXANE in Untreated Metastatic NSCLCCompletedNCT03573947Phase 2Results posted
• Immunotherapy in Patients With Metastatic Cancers and CDK12 MutationsCompletedNCT03570619Phase 2Results posted
• Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell CarcinomaTerminatedNCT03552380Phase 2Results posted
• Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the LiverCompletedNCT03472586Phase 2Results posted
• Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results posted
• Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)TerminatedNCT03461952Phase 2Results posted
• An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT03459222Phase 1/2Results posted
• A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory MelanomaTerminatedNCT03445533Phase 3Results posted
• PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRCCompletedNCT03442569Phase 2Results posted
• Trial of Combination Tumor Treating Fields (TTF; Optune), Nivolumab Plus/Minus Ipilimumab for Recurrent GlioblastomaTerminatedNCT03430791Phase 2Results posted
• Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCTerminatedNCT03425331Phase 2Results posted
• Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsTerminatedNCT03420521Phase 2Results posted
• Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)TerminatedNCT03406715Phase 2Results posted
• Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based ChemotherapyCompletedNCT03404960Phase 1/2Results posted
• A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced CancersCompletedNCT03400332Phase 1/2Results posted
• Prostaglandin Inhibition and Immune Checkpoint Blockade in MelanomaCompletedNCT03396952Phase 2Results posted
• Recombinant Interleukin-15 in Combination With Checkpoint Inhibitors Nivolumab and Ipilimumab in People With Refractory CancersCompletedNCT03388632Phase 1Results posted
• An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has SpreadCompletedNCT03377361Phase 1/2Results posted
• Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung CancerActive, not recruitingNCT03377023Phase 1/2Results posted
• Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated GlioblastomaCompletedNCT03367715Phase 2Results posted
• Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)CompletedNCT03302234Phase 3Results posted
• Adoptive Cell Therapy Across Cancer DiagnosesCompletedNCT03296137Phase 1/2Results posted
• Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)CompletedNCT03285321Phase 2Results posted
• Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Renal Medullary CarcinomaTerminatedNCT03274258Phase 2Results posted
• Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS MutationCompletedNCT03271047Phase 2Results posted
• Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLCCompletedNCT03256136Phase 2Results posted
• A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid TumorsTerminatedNCT03251924Phase 1/2Results posted
• Nivolumab Plus Ipilimumab in Thyroid CancerCompletedNCT03246958Phase 2Results posted
• Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerCompletedNCT03222076Phase 2Results posted
• A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCCompletedNCT03215706Phase 3Results posted
• A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid TumorsCompletedNCT03195478Phase 1/2Results posted
• Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland CancerCompletedNCT03172624Phase 2Results posted
• Radiation and Immune Checkpoints Blockade in Metastatic NSCLC (BMS # CA209-632)TerminatedNCT03168464Phase 1/2Results posted
• Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerCompletedNCT03158129Phase 2Results posted
• Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland CancerActive, not recruitingNCT03146650Phase 2Results posted
• A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCompletedNCT03143153Phase 3Results posted
• A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results posted
• A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a KidneyCompletedNCT03138512Phase 3Results posted
• A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) MalignanciesCompletedNCT03130959Phase 2Results posted
• Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell CarcinomaCompletedNCT03117309Phase 2Results posted
• Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract CancerCompletedNCT03101566Phase 2Results posted
• An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCompletedNCT03068455Phase 3Results posted
• Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerCompletedNCT03043599Phase 1/2Results posted
• Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial CancerActive, not recruitingNCT03036098Phase 3Results posted
• An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell CarcinomaCompletedNCT03029780Phase 2Results posted
• A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung CancerTerminatedNCT03026166Phase 1/2Results posted
• PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or LymphomasTerminatedNCT03013491Phase 1/2Results posted
• An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03001882Phase 2Results posted
• A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02998528Phase 3Results posted
• A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)CompletedNCT02985957Phase 2Results posted
• A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell CancerCompletedNCT02982954Phase 4Results posted
• A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With IpilimumabTerminatedNCT02978443Phase 2Results posted
• Study of Combination of Ipilimumab and Nivolumab in Patients With MelanomaCompletedNCT02970981Phase 2Results posted
• Ipilimumab and Nivolumab in Leptomeningeal MetastasesCompletedNCT02939300Phase 2Results posted
• A Study to Test Combination Treatments in Participants With Advanced Gastric CancerCompletedNCT02935634Phase 2Results posted
• Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral CavityActive, not recruitingNCT02919683Phase 2Results posted
• A Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Advanced Solid TumorsCompletedNCT02913313Phase 1/2Results posted
• A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With MelanomaCompletedNCT02905266Phase 3Results posted
• JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid TumorsCompletedNCT02904226Phase 1/2Results posted
• Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsCompletedNCT02899299Phase 3Results posted
• Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast CancerTerminatedNCT02892734Phase 2Results posted
• Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid LeukemiaActive, not recruitingNCT02890329Phase 1Results posted
• Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaActive, not recruitingNCT02879695Phase 1Results posted
• Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction CancerCompletedNCT02872116Phase 3Results posted
• A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyCompletedNCT02864251Phase 3Results posted
• A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast CancerCompletedNCT02833233Not applicableResults posted
• Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02823574Phase 2Results posted
• Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersActive, not recruitingNCT02785952Phase 3Results posted
• An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung CancerTerminatedNCT02750514Phase 2Results posted
• Pembrolizumab and Ipilimumab After Prior Immunotherapy for MelanomaActive, not recruitingNCT02743819Phase 2Results posted
• Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedNCT02741570Phase 3Results posted
• An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have SpreadCompletedNCT02737475Phase 1/2Results posted
• Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedNCT02723006Phase 1Results posted
• A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic MelanomaCompletedNCT02714218Phase 3Results posted
• Check Point Inhibition After Autologous Stem Cell Transplantation in Patients at High Risk of Post Transplant RecurrenceTerminatedNCT02681302Phase 1/2Results posted
• Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV MelanomaCompletedNCT02659540Phase 1Results posted
• An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have SpreadCompletedNCT02658890Phase 1/2Results posted
• An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent MeningiomaActive, not recruitingNCT02648997Phase 2Results posted
• A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic MelanomaCompletedNCT02644967Phase 2Results posted
• Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced MelanomaCompletedNCT02599402Phase 3Results posted
• Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)CompletedNCT02553642Phase 2Results posted

← Ipilimumab overview